What the company does
Withus Pharmaceutical makes finished prescription medicines, including treatments for high blood pressure, high cholesterol, hardening of the arteries, bone and joint conditions, digestive disorders, infections, and central-nervous-system conditions, targeting the chronic diseases common in an ageing population.
Its products are distributed through a nationwide sales network to hospitals, clinics, and pharmacies across South Korea. Listed on KOSDAQ, South Korea's tech and small-cap board, the company earns the largest share of its revenue from cardiovascular medicines, with its cholesterol-lowering tablet Atoren (atorvastatin), a generic version of a widely used branded drug, as its leading product.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$58.1M
- FY2024US$74.4M
- FY2025US$77.1M
Operating profit
- FY2023US$5.7M
- FY2024US$4.1M
- FY2025US$4.1M
Net income
- FY2023US$5.8M
- FY2024US$3.5M
- FY2025US$3.6M
Key ratios (FY2025)
Why it matters · Context, not a recommendation
Alongside its own branded generics, the company also manufactures finished medicines on behalf of other pharmaceutical firms under contract manufacturing (CMO) arrangements, a segment it is actively expanding.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?